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Abstract Modified vaccinia virus Ankara (MVA), a host range 
restricted and highly attenuated vaccinia virus strain, is unable 
to multiply in human and most other mammalian cell lines. Since 
viral gene expression is unimpaired in non-permissive c lls recom- 
binant MVA viruses are efficient as well as exceptionally safe 
expression vectors. We constructed a recombinant MVA that 
expresses the bacteriophage T7 RNA polymerase and tested its 
usefulness for transient expression of recombinant genes under 
the control of a T7 promoter. Using the chloramphenicol ace- 
tyltransferase (CAT) gene as a reporter gene, infection with 
MVA-T7pol allowed efficient synthesis of recombinant enzyme 
in mammalian cells. Despite the severe host restriction of MVA, 
enzyme activities induced by infection with MVA-T7pol were 
similar to those determined after infection with a replication- 
competent vaccinia-T7pol recombinant virus. Thus, MVA-T7pol 
may be used as a novel vaccinia vector to achieve T7 RNA 
polymerase-specific recombinant gene expression in the absence 
of productive vaccinia virus replication. 
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1. Introduction 
Recombinant vaccinia virus expressing the bacteriophage T7
RNA polymerase gene allowed the establishment of widely 
applicable vector systems for the synthesis of recombinant pro- 
teins in mammalian cells [1]. In all protocols, recombinant gene 
expression relies on the synthesis of the T7 RNA polymerase 
in the cytoplasm of vaccinia virus infected eukaryotic ells. 
Most popular became a protocol for transient gene expression 
[2]. First, a foreign gene of interest is inserted into a plasmid 
under the control of the T7 RNA polymerase promoter. In the 
following, this plasmid is introduced into the cytoplasm of cells 
infected with the recombinant vaccinia virus producing T7 
RNA polymerase using standard transfection procedures. The 
transient expression system is simple because no new recombi- 
nant viruses need to be made and very efficient with usually 
greater than 80% of the cells expressing the gene of interest [3]. 
The advantage over other transient expression systems is very 
likely its independence on the transport of plasmids to the 
cellular nucleus. The vaccinia virus/T7 RNA polymerase tran- 
sient expression system has already been proven extremely suc- 
cessful to analysis of structure and function of viral proteins 
[4~6], rescue of mutant viruses [7], virus assembly and synthesis 
of defective viral pseudo-particles [8], and expression of eukar- 
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yotic polypeptides such as ion channels [9] or neurotransmitter 
receptors [10]. 
However, vaccinia virus, despite its historical use as a vac- 
cine, is infectious for humans and for its use as expression 
vector in the laboratory precautions were taken and safety 
regulations have been established [11]. To overcome this limita- 
tion of the use of vaccinia virus with the T7 system, adoption 
of highly attenuated viruses would be desirable. Furthermore, 
important future applications of the system, e.g. the generation 
of recombinant proteins or recombinant viral particles for ther- 
apeutic or prophylactic use in humans, could be impeded by the 
productive replication of the recombinant vaccinia virus. 
Recently, a novel vaccinia vector system was established on 
the basis of the host range restricted and highly attenuated 
modified vaccinia Ankara (MVA) strain of vaccinia virus [12]. 
Derived by longterm serial passage in chicken embryo fibro- 
blasts, MVA lost its capacity to grow productively in human 
and most other mammalian cells [13-15]. Viral replication in 
human cells is blocked late in infection preventing the assembly 
to mature infectious virions. Nevertheless, MVA is able to 
express viral and recombinant genes at high levels even in 
non-permissive cells and can serve as an efficient and exception- 
ally safe expression vector [16]. To further exploit the use of 
MVA we constructed recombinant viruses that allow expres- 
sion of the bacteriophage T7 RNA polymerase gene under the 
control of the vaccinia virus early/late promoter P7.5. The use- 
fulness of MVA-T7pol recombinant viruses as expression sys- 
tem was tested by the co-transfection f plasmid DNA contain- 
ing the E. coli CAT gene under the control of a T7 RNA 
polymerase promoter. We demonstrate h re that highly attenu- 
ated MVA vectors can be used in the vaccinia virus-T7 RNA 
polymerase expression system as efficiently as a fully replica- 
tion-competent recombinant vaccinia virus. 
2. Materials and methods 
2.1. Cells and viruses 
Cells were maintained in a humidified ai~5% CO2 atmosphere at
37°C. Human HeLa, monkey CV-1 and chicken embryo fibroblast cells 
(CEF) were grown in RPMI 1640 medium supplemented with 10% fetal 
calf serum (FCS). Vaccinia virus strain MVA was routinely propagated 
and titered by endpoint dilution in CEF to obtain the 50% tissue culture 
infectious dose (TCIDs0). Recombinant vaccinia virus (strain Western 
Reserve) vTF7-3 was kindly provided by B. Moss (Laboratory of Viral 
Diseases, NIAID, NIH, Bethesda, USA)and propagated inCVol cells 
and titered in CEF (TCID50). 
2.2. Plasmid constructions 
Sequences ofMVA DNA flanking the site of a 2500-bp deletion in 
the HindIII N fragment of the MVA genome [17] were amplified by 
PCR and cloned into pUC18. The primers for the left 600-bp DNA 
flank were 5'-CAG CAG GGT ACC CTC ATC GTA CAG GAC GTT 
CTC-3" and 5'-CAG CAG CCC GGG TAT TCG ATG ATT ATT 
TTT AAC AAA ATA ACA-Y (sites for restriction enzymes KpnI and 
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Smal are underlined). The primers for the right 550-bp DNA flank were 
5'-CAG CAG CTG CAG GAA TCA TCC ATT CCA CTG AAT 
AGC-3' and 5'-CAG CAG GCA TGC CGA CGA ACA AGG AAC 
TGT AGC AGA-3' (sites for restriction enzymes PstI and SphI are 
underlined). Between these flanks of MVA DNA, the Escherichia eoli 
lacZ gene under control of the vaccinia virus late promoter P11 was 
inserted to generate the plasmid pUCII LZ. In the following, a 3.1 kbp 
DNA fragment containing the entire gene of bacteriophage T7 RNA 
polymerase under control of the vaccinia virus early/late promoter P7.5 
was excised with EcoRI from plasmid pTF7-3 [2], and cloned into a 
unique SmaI restriction site of pUCII LZ to make the plasmid transfer 
vector pUCII LZ T7pol. 
2.3. Generation of recombinant viruses 
CEF infected with MVA at a multiplicity of 0.05 TCIDs0 per cell were 
transfected with plasmid as described previously [18]. Recombinant 
MVA virus expressing the T7 RNA polymerase and co-expressing 
fl-galactosidase (MVA P7.5-T7pol) was selected by five consecutive 
rounds of plaque purification in CEF stained with 5-bromo-4-chloro- 
3-indolyl fl-D-galactoside (300/.tg/ml) [19]. Subsequently, recombinant 
viruses were amplified by infection of CEF monolayers, and the DNA 
was analyzed by PCR. 
2.4. Analysis of [35 S]methionine-labeled polypeptides 
Transfected or untransfected cell monolayers grown in 12-well plates 
were infected with virus at a multiplicity of 20 TCIDs0 per cell. At 2 5 
h after infection, the medium was removed, and the cultures were 
washed once with 1 ml of methionine-free medium. To each well, 0.2 
ml of methionine-free medium supplemented with 50 /ICi of 
[35S]methionine was added and incubated for 30 min or overnight at 
37°C. Cytoplasmic extracts of infected cells were prepared by incubat- 
ing each well in 0.2 ml of 0.5% Nonidet P-40 lysis buffer for 10 min at 
37°C and samples were analyzed by SDS-PAGE. 
2.5. Chloramphenicol acetyltramferase (CAT) assay 
CV-1 cells in 12-well tissue-culture plates were transfected with 10/.tg 
pOS6 (derived from pTM1 [1] containing the E. coli CAT gene under 
control of T7 RNA polymerase promoter and kindly provided by B. 
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Fig. l. Schematic map of the genome of MVA and plasmid pUCII LZ 
T7pol designed for insertion of the bacteriophage T7 RNA polymerase 
gene by homologous recombination. HindIII restriction endonuclease 
sites within the genome of MVA are indicated at the top (kb, kilobase 
pairs). DNA sequences (flank 1 and flank 2) adjacent to deletion II 
within the HindIII N fragment [17] (affecting the three open-reading 
frames M1L, M2L, and K1L present in the Western Reserve strain of 
vaccinia virus) were cloned to allow recombination i to the MVA 
genome. Cassettes for the expression of the genes of bacteriophage T7
RNA polymerase and E. coli lacZ were inserted between the MVA 
DNA flanks. Pll and P7.5 refer to well-characterized late and early/late 
vaccinia virus promoters, respectively. 
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Fig. 2. Expression of the bacteriophage T7 RNA polymerase gene by 
MVA recombinant virus. SDS/PAGE of CV-1 cells infected with MVA 
LZ T7pol (lane 1), or MVA (lane 2). The infected cultures were labeled 
with [35S]methionine at 5 h postinfection. Cell lysates were analyzed by 
electrophoresis ona 10% polyacrylamide g l. Lane 3 = uninfected CV-1 
cell extract. The numbers on the left indicate the positions and molec- 
ular masses (in kDa) of protein standards. The protein band represent- 
ing the enzyme T7 RNA polymerase is marked by an arrow, the posi- 
tion of the marker protein fl-galactosidase i  indicated by an arrowhead. 
Moss, NIH, Bethesda, USA) and infected with 20 TCIDs0 recombinant 
vaccinia virus per cell. At 12 h after infection cells were suspended in
0.2 ml of 0.25 M Tris-HC1 (pH 7.5). After three freez~thaw cycles, the 
lysates were cleared by centrifugation, the protein content of the super- 
natants was determined [20], and samples containing 0.5, 0.25, 0.1/Jg 
total protein were assayed for enzyme activity as described by Mackett 
et al [21]. After autoradiography, labeled spots were quantitated using 
an imaging analyzer (Fujix BAS 1000, Fuji, Japan). 
3. Results and discussion 
3.1. Construction and isolation of  MVA recombinants 
expressing the T7 RNA polymerase gene 
Previous work demonstrated that MVA may serve as effi- 
cient expression vector in human and other mammal ian cells 
where it is unable to produce infectious progeny [16]. To test 
the usefulness of  MVA recombinants in a hybrid expression 
system relying on the bacteriophage T7 RNA polymerase, an 
enzyme with exceptional transcription activity [22,23], we con- 
structed the MVA plasmid transfer vector pUC II LZ T7pol 
(Fig. 1). The vector plasmid contains MVA DNA sequences 
adjacent to a deletion of 2500 bp affecting the three open 
reading frames M1L, M2L, and K1L present in the Western 
Reserve strain of vaccinia virus [17]. These flanking sequences 
target the insertion of the foreign genes precisely to the site of 
this naturally occuring deletion in the MVA genome. For  ex- 
pression of the bacteriophage T7 RNA polymerase gene we 
chose the well-characterized vaccinia virus early/late promoter  
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Fig. 3. Transient expression of CAT using vaccinia-T7 RNA polym- 
erase recombinant viruses. SDS/PAGE of human HeLa cells trans- 
fected with pOS6 and infected with MVA (lane 1), vTF7-3 (lane 2), or 
MVA-T7pol (lane 3). The infected cultures were labeled overnight with 
[35S]methionine at 6 h after transfection. Cell lysates were analyzed by 
electrophoresis ona 10% polyacrylamide g l. The numbers on the left 
indicate the positions and molecular masses (in kDa) of protein 
standards. The protein band representing the enzyme CAT is marked 
by an arrowhead. 
P7.5 as transcriptional regulator. The identical promoter has 
been used to construct he replication-competent WR recom- 
binant virus vTF7-3 [2] that is commonly used in established 
vaccinia virus/T7 polymerase expression systems. 
Recombinant vaccinia virus MVA-T7pol was formed in CEF 
that were infected with MVA and transfected with pUCII LZ 
T7pol. Recombinant virus plaques were identified by screening 
for fl-galactosidase production with a chromogenic substrate 
[19]. Multiple plaque isolations were performed, and the correct 
insertion of the foreign DNA and absence of parental virus was 
ascertained by PCR analysis. 
3.2. Characterization of  expressed recombinant proteins 
A basic protocol [3] describing the vaccinia virus/T7 RNA 
polymerase system for transient expression of recombinant 
genes recommends transfection and infection of monkey CV-1 
cells. When we characterized viral gene expression in this cell 
line metabolic labeling with [35S]methionine of cells infected 
with MVA T7pol revealed the synthesis of two additional pol- 
ypeptides (Fig. 2). One protein band of about 116,000 Da 
(marked by an arrowhead) was likely to represent the E. coli 
fl-galactosidase that is co-expressed as a marker enzyme to 
allow screening for recombinant virus. The strong expression 
activity mediated by the vaccinia virus late promoter P11 is 
nicely seen in the large amount offl-galactosidase made. An- 
other additional band (marked by an arrow) migrated as a 
polypeptide of about 98,000 Da, the expected size of the 
bacteriophage T7 RNA polymerase [24]. This single-subunit 
enzyme has an extremely high transcriptase activity. Therefore, 
overexpression f the catalytic polypeptide is not needed and 
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even might not be desirable. We chose the vaccinia virus early/ 
late promoter P7.5 to control expression of the T7 RNA polym- 
erase. The advantage of a promoter system suitable for both 
vaccinia virus early and late transcription is that synthesis of 
recombinant T7-RNA polymerase is induced immediately after 
viral entry and maintained uring the complete cycle of vac- 
cinia viral gene expression. 
3.3. Transient expression of CAT in MVA T7pol infected cells 
To determine whether bacteriophage T7 RNA polymerase 
made by recombinant MVA can function in mammalian cells, 
we used the E. coli CAT gene with a T7 promoter as target gene 
in transient ransfection assays. Additionally, we chose for 
comparative purposes the well-characterized Western Reserve 
strain recombinant virus vTF7-3 that contains the identical 
P7.5 promoter-T7pol expression cassette but that multiplies 
well in human cells. In a first experiment human HeLa cells 
were transfected with plasmid pOS6 containing the CAT gene 
and infected with MVA-T7pol, vTF7-3 or MVA. Protein syn- 
thesis was monitored by SDS/PAGE of cytoplasmic proteins 
from cells in vivo-labeled with [35S]methionine at two hours 
after infection (Fig. 3). A band corresponding in size to the 
CAT polypeptide, was clearly seen among the proteins from 
cells infected with MVA-T7pol (lane 3) or vTF7-3 (lane 2). The 
extract of cells infected with MVA alone (lane 1) contained a
minor amount of a polypeptide that migrated with almost he 
same molecular weights as CAT representing, most likely, a 
vaccinia viral or cellular protein of similar size. To our surprise 
and despite the inability of MVA to replicate productively in 
human HeLa cells, the amount of recombinant CAT produced 
in MVA-T7pol infected cells seemed to be higher than that 
made in cells infected with the replicating recombinant vaccinia 
virus vTF7-3. For further comparison in a more quantitative 
manner, a second series of experiments was performed in CV-1 
cells. Again transfection of pOS6 was followed by infection 
with the recombinant vaccinia viruses expressing the T7 RNA 
polymerase. It is noteworthy that MVA-T7pol, in sharp con- 
trast to vTF7-3, produced no visible cytopathogenic effects in 
the mammalian cell lines HeLa and CV-1 even at high multi- 
plicities of infection (MOI). At 24 hours after infection cell 
extracts were made, diluted, and tested for CAT activity by 
MVA-T7pol vTF7-3 MVA 
gg protein 0.5 0.25 0.1 0.5 0.25 0.1 0.5 0.25 
3-AcC 
1-AcC 
% AcC 89 75 31 51 40 25 4 5 
Fig. 4. CAT activity in lysates from C¥-1 cells transfected with pOS6 
and infected with MVA T7pol, vTF7-3, or MVA. Cell lysates were 
prepared 12 h after infection and aliquots containing 0.1, 0.25 and 0.5 
/lg total protein were assayed for CAT. An autoradiogram is shown, 
with the positions of chloramphenicol (C) and acetylated forms of 
chloramphenicol (AcC). CAT activity is expressed as percentage of 
acetylated product formed in 60 min. 
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measuring the conversion of [14C]chloramphenicol to acetylated 
derivates eparable by thin-layer silica gel chromatography. As
illustrated by the autoradiogram in Fig. 4, only background 
acetylation activity was detectable in extracts of MVA infected 
CV-1 cells that had been transfected with pOS6. In contrast, 
[14C]chloramphenicol was acetylated efficiently when added to 
extracts of cells infected with recombinant viruses MVA-T7pol 
or vTF7-3. Interestingly, enzyme activities detected in extracts 
of MVA-T7pol infected cells were at least equal to those found 
in extracts from CV-1 cells infected with vTF7-3. These results 
indicate that the recombinant vector MVA-T7pol can be used 
very efficiently for the expression of T7-ptomoter controlled 
target genes in mammalian cell lines. The level of gene expres- 
sion achieved with MVA-T7pol in transient assays was in the 
same range as obtained with a replication competent and pre- 
sumedly much more virulent recombinant vaccinia virus. 
In conclusion, the replication-deficient virus MVA-T7pol 
represents an important addition to already vaccinia/T7 polym- 
erase expression systems and its adoption should drastically 
reduce the risk of infecting laboratory workers. Besides of this 
safety aspect, lack of viral replication and low cytopathogen- 
icity in mammalian cells, characteristic features of the parent 
MVA virus, may significantly expand the power of the hybrid 
vaccinia virus/T7 RNA polymerase expression system. Promis- 
ing future applications of MVA-T7pol vectors should include 
both functional analysis of recombinant genes in eukaryotic 
environment and production of recombinant proteins for the 
development of new therapeutics or vaccines. 
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